BRPI0513904A - forma farmacêutica de multipartìcula para substáncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica - Google Patents
forma farmacêutica de multipartìcula para substáncias ativas de baixa solubilidade e um processo para preparar a forma farmacêuticaInfo
- Publication number
- BRPI0513904A BRPI0513904A BRPI0513904-0A BRPI0513904A BRPI0513904A BR PI0513904 A BRPI0513904 A BR PI0513904A BR PI0513904 A BRPI0513904 A BR PI0513904A BR PI0513904 A BRPI0513904 A BR PI0513904A
- Authority
- BR
- Brazil
- Prior art keywords
- active agent
- pharmaceutical form
- matrix
- multiparticulate
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
FORMA FARMACêUTICA DE MULTIPARTìCULA PARA SUBSTáNCIAS ATIVAS DE BAIXA SOLUBILIDADE E UM PROCESSO PARA PREPARAR A FORMA FARMACêUTICA. A presente invenção refere-se a uma forma de dosagem farmacêutica de multipartícula na forma de receptáculo reduzindo os valores de pH do estómago, contendo uma pluralidade de péletes, partículas, grânulos ou aglomerados cujo diâmetro médio varia de 50 a 2500 <109>m substancialmente consistindo em a) uma camada de matriz interna contendo um agente ativo não é peptídeo ou proteína, nem os derivados ou conjugados destes, uma matriz lipofílica cujo ponto de fusão é maior do que 37<198>C e um polímero com efeito mucoadesivo, b) um revestimento de película externa substancialmente consistindo em um polímero ou um copolímero aniónico que é opcionalmente formulado com aditivos farmacêuticos convencionais, em que o agente ativo tem uma solubilidade de água de acordo com DAB 10, de pelo menos 30 partes em volume de água para uma parte em peso do agente ativo e é revestido com a matriz lipofílica e o referido agente ativo contendo matriz lipofílica é revestido com uma matriz feita a partir de um polímero com efeito mucoadesivo. Um método para produzir a dosagem farmacêutica de multipartícula inventiva é da mesma forma descrito.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004036437A DE102004036437A1 (de) | 2004-07-27 | 2004-07-27 | Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| PCT/EP2005/007427 WO2006010453A1 (de) | 2004-07-27 | 2005-07-08 | Multipartikuläre arzneiform für wenig lösliche wirkstoffe sowie ein verfahren zur herstellung der arzneiform |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0513904A true BRPI0513904A (pt) | 2008-05-20 |
| BRPI0513904B1 BRPI0513904B1 (pt) | 2019-02-05 |
| BRPI0513904B8 BRPI0513904B8 (pt) | 2021-05-25 |
Family
ID=35169905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513904A BRPI0513904B8 (pt) | 2004-07-27 | 2005-07-08 | forma farmacêutica de multipartícula para substâncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8273375B2 (pt) |
| EP (1) | EP1771157B1 (pt) |
| JP (1) | JP5455305B2 (pt) |
| KR (1) | KR101216750B1 (pt) |
| AT (1) | ATE388692T1 (pt) |
| BR (1) | BRPI0513904B8 (pt) |
| CA (1) | CA2570608C (pt) |
| DE (2) | DE102004036437A1 (pt) |
| ES (1) | ES2302209T3 (pt) |
| IL (1) | IL180943A (pt) |
| MX (1) | MX2007000955A (pt) |
| PL (1) | PL1771157T3 (pt) |
| SI (1) | SI1771157T1 (pt) |
| WO (1) | WO2006010453A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10332160A1 (de) * | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| DE102004059792A1 (de) * | 2004-12-10 | 2006-06-14 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| DE102005007059A1 (de) | 2005-02-15 | 2006-08-24 | Röhm GmbH & Co. KG | Teilneutralisiertes anionisches (Meth)acrylat-Copolymer |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| DE102006035549A1 (de) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
| DE102007031697A1 (de) | 2007-07-06 | 2009-01-08 | Walter Rau Neusser Öl und Fett AG | Kosmetische oder pharmazeutische Zubereitung |
| BR112012021445B8 (pt) | 2010-02-25 | 2022-07-05 | Evonik Roehm Gmbh | formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| EP2661266B1 (en) | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| WO2012109216A1 (en) | 2011-02-11 | 2012-08-16 | Zx Pharma, Llc | Multiparticulate l-menthol formulations and related methods |
| JP5832645B2 (ja) * | 2011-06-17 | 2015-12-16 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ | 医薬剤形又は栄養補助剤形に適したコーティング組成物 |
| KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CA2909591C (en) | 2013-04-23 | 2017-03-28 | Zx Pharma, Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
| JP6458322B2 (ja) * | 2013-05-06 | 2019-01-30 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | 粉末状ビタミンｅ製剤 |
| US20160022644A1 (en) * | 2014-07-22 | 2016-01-28 | Tsu-I Catherine Wang | Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility |
| US10588866B2 (en) | 2014-11-11 | 2020-03-17 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
| EP3313380A4 (en) * | 2015-06-26 | 2019-03-20 | Advanced BioNutrition Corp. | COMPOSITION FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES TO AN ANIMAL |
| MX2020012459A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| IT202000009922A1 (it) * | 2020-05-05 | 2021-11-05 | Vetagro Int S R L | Composizioni comprendenti timolo per uso nel trattamento di disturbi intestinali infiammatori o funzionali mediante modulazione del sistema endocannabinoide |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN115154661A (zh) * | 2022-07-29 | 2022-10-11 | 广州莱度品牌管理有限公司 | 一种仿生角质膜的制备方法 |
| WO2025043236A1 (en) * | 2023-08-24 | 2025-02-27 | Joseph Fuisz | Edible oral films, compositions, method of manufacture and packaging systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW209174B (pt) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
| US5938990A (en) * | 1994-07-01 | 1999-08-17 | Roche Vitamins Inc. | Encapsulation of oleophilic substances and compositions produced thereby |
| US20030017195A1 (en) | 2001-07-20 | 2003-01-23 | Samir Mitragotri | Method for oral drug delivery |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| DE10332160A1 (de) * | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
| US20040224019A1 (en) | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
-
2004
- 2004-07-27 DE DE102004036437A patent/DE102004036437A1/de not_active Withdrawn
-
2005
- 2005-07-08 KR KR1020077002117A patent/KR101216750B1/ko not_active Expired - Fee Related
- 2005-07-08 JP JP2007522954A patent/JP5455305B2/ja not_active Expired - Fee Related
- 2005-07-08 SI SI200530221T patent/SI1771157T1/sl unknown
- 2005-07-08 BR BRPI0513904A patent/BRPI0513904B8/pt not_active IP Right Cessation
- 2005-07-08 DE DE502005003223T patent/DE502005003223D1/de not_active Expired - Lifetime
- 2005-07-08 CA CA2570608A patent/CA2570608C/en not_active Expired - Lifetime
- 2005-07-08 AT AT05758133T patent/ATE388692T1/de active
- 2005-07-08 MX MX2007000955A patent/MX2007000955A/es active IP Right Grant
- 2005-07-08 EP EP05758133A patent/EP1771157B1/de not_active Expired - Lifetime
- 2005-07-08 PL PL05758133T patent/PL1771157T3/pl unknown
- 2005-07-08 ES ES05758133T patent/ES2302209T3/es not_active Expired - Lifetime
- 2005-07-08 WO PCT/EP2005/007427 patent/WO2006010453A1/de not_active Ceased
- 2005-07-08 US US11/572,720 patent/US8273375B2/en not_active Expired - Fee Related
-
2007
- 2007-01-25 IL IL180943A patent/IL180943A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2570608A1 (en) | 2006-02-02 |
| IL180943A0 (en) | 2007-07-04 |
| JP5455305B2 (ja) | 2014-03-26 |
| DE502005003223D1 (de) | 2008-04-24 |
| EP1771157A1 (de) | 2007-04-11 |
| BRPI0513904B1 (pt) | 2019-02-05 |
| MX2007000955A (es) | 2007-04-16 |
| PL1771157T3 (pl) | 2008-08-29 |
| KR20070046089A (ko) | 2007-05-02 |
| DE102004036437A1 (de) | 2006-03-23 |
| EP1771157B1 (de) | 2008-03-12 |
| CA2570608C (en) | 2015-07-07 |
| US8273375B2 (en) | 2012-09-25 |
| ATE388692T1 (de) | 2008-03-15 |
| WO2006010453A1 (de) | 2006-02-02 |
| ES2302209T3 (es) | 2008-07-01 |
| IL180943A (en) | 2010-12-30 |
| SI1771157T1 (sl) | 2008-06-30 |
| JP2008508204A (ja) | 2008-03-21 |
| BRPI0513904B8 (pt) | 2021-05-25 |
| KR101216750B1 (ko) | 2012-12-28 |
| US20080166416A1 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513904A (pt) | forma farmacêutica de multipartìcula para substáncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica | |
| WO2005007139A3 (de) | Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform | |
| BRPI0409334A (pt) | pelìcula de gel termorreversìvel, homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e cápsulas moles, e, forma sólida | |
| EA201400972A1 (ru) | Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения | |
| BRPI0807569A8 (pt) | Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico | |
| BR0311908A (pt) | Composição farmacêutica para liberação controlada de substâncias ativas e seu método de fabricação | |
| JP2007537283A5 (pt) | ||
| DK1553927T3 (da) | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger | |
| BR9806738A (pt) | Composição farmacêutica de fenofibrato dotada de alta biodisponibilidade, e método para a sua preparação. | |
| HRP20100372T1 (hr) | Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba | |
| NZ778023A (en) | Colonic drug delivery formulation | |
| KR930003905A (ko) | 약학적 결합 제제 | |
| BRPI0515815A (pt) | forma medicamentosa de multipartìculas contendo substáncias ativas de ácido nucléico formuladas mucoadesivas bem como processo para preparação da forma medicamentosa | |
| BR0202491A (pt) | Forma de dosagem de núcleo macio, de revestimento frágil | |
| BRPI0417043A (pt) | composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição | |
| RU2009109353A (ru) | Композиции на основе наночастиц | |
| Odeku et al. | Formulation and in vitro evaluation of natural gum-based microbeads for delivery of ibuprofen. | |
| Bharti et al. | Development of nitazoxanide-loaded colon-targeted formulation for intestinal parasitic infections: centre composite design-based optimization and characterization | |
| Shankar et al. | Development and characterization of bioadhesive gel of microencapsulated metronidazole for vaginal use | |
| BR0312206A (pt) | Formulações de pélete esférico | |
| CO5690532A2 (es) | Formas de dosificacion farmaceutica de liberacion extendida | |
| Sharma et al. | Formulation and in vitro characterization of cefpodoxime proxetil gastroretentive microballoons | |
| CN105362211B (zh) | 纳米金属氧化物-米诺环素纳米缓释凝胶及其制备方法和应用 | |
| Pahwa et al. | Gastroretentive floating technology for eradication of helicobacter pylori: an insight view | |
| JP2004535417A5 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: EVONIK ROEHM GMBH (DE) Free format text: NOME ALTERADO DE: ROEHM GMBH |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25D | Requested change of name of applicant approved |
Owner name: ROEHM GMBH (DE) |
|
| B25G | Requested change of headquarter approved |
Owner name: ROEHM GMBH (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: EVONIK DEGUSSA GMBH (DE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: EVONIK OPERATIONS GMBH (DE) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2840 DE 10-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |